GlassScriptPhysician profile
Luis R Espinoza
NPI 1881616688
$11,437.41
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $66.37 · 2022: $48.81 · 2023: $138 · 2024: $16.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer International LLC | $9,533.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $364.24 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $311.81 | 2019-2020 | |
| Abbvie INC. | $239.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $220.66 | 2019 | |
| Pfizer INC. | $168.97 | 2019 | |
| Ucb, INC. | $128.81 | 2019 | |
| Janssen Biotech, INC. | $116.91 | 2019-2020 | |
| Amgen INC. | $104.24 | 2019-2020 | |
| Celgene Corporation | $50.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.15 | 2019 | |
| Genentech USA, INC. | $29.74 | 2019 | |
| Abbott Laboratories | $19.11 | 2019 | |
| Hikma Pharmaceuticals USA | $18.26 | 2019 | |
| Janssen Scientific Affairs, LLC | $17.65 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.47 | 2019 | |
| Antares Pharma, INC. | $15.09 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $14.92 | 2019 | |
| Horizon Therapeutics Plc | $14.46 | 2019 | |
| Qiagen, LLC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.